Investigate TRIANGLE PARK, N.C.- - (BUSINESS WIRE)- - TransEnterix, Inc. (NYSE MKT: TRXC), a therapeutic gadget organization that is spearheading the utilization of mechanical autonomy to enhance insignificantly intrusive surgery, today declared that it will show and highlight the Senhance™ Surgical Robot System (the "Senhance") at the 45th American Association of Gynecologic Laparoscopists (AAGL) Global Congress. The congress will be hung on November 16-18, 2016 in Orlando, FL.
The Senhance will be accessible for specialist assessments at the congress. Specialists may plan framework assessments by joining at the TransEnterix corner. Dr. Salvatore Gueli Alletti from the Division of Gynecologic Oncology at the Catholic University of the Sacred Heart in Rome, Italy, will feature an extraordinary symposium committed to the clinical experience of the Senhance in Gynecologic Surgery. The symposium will be hung on the morning of Wednesday, November 16, 2016, and members must enroll through the AAGL to go to.
The Senhance conveys the CE Mark for use all in all surgery, gynecology, urology and thoracic surgery yet is not accessible available to be purchased in the US. TransEnterix is setting up a 510(k) accommodation for the Senhance.
About TransEnterix
TransEnterix is a restorative gadget organization that is spearheading the utilization of apply autonomy to enhance negligibly intrusive surgery by tending to the clinical and monetary difficulties connected with current laparoscopic and mechanical alternatives. The organization is centered around the commercialization of the Senhance Surgical Robotic System, a multi-port automated framework that conveys the benefits of mechanical surgery to patients while empowering specialists with imaginative innovation, for example, haptic input and eye detecting camera control. The organization is likewise building up the SurgiBot™ System, a solitary port, mechanically upgraded laparoscopic surgical stage. The Senhance Surgical Robotic System has been allowed a CE Mark however is not right now accessible available to be purchased in the United States. For more data, visit the TransEnterix site at www.transenterix.com.
Forward Looking Statements
This official statement incorporates articulations identifying with The Senhance™ Surgical Robotic System and our current administrative and commercialization gets ready for this item. These announcements and different articulations in regards to our feasible arrangements and objectives constitute "forward looking proclamations" inside the importance of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are proposed to meet all requirements for the protected harbor from obligation set up by the Private Securities Litigation Reform Act of 1995. Such proclamations are liable to dangers and vulnerabilities that are frequently hard to foresee, are outside our ability to control and which may make comes about vary tangibly from desires, including whether and when we will set up a 510(k) accommodation for the Senhance Surgical Robotic System. For a dialog of the dangers and vulnerabilities connected with TransEnterix's business, please audit our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K documented on March 3, 2016 and our different filings we make with the SEC. You are advised not to place undue dependence on these forward looking articulations, which depend on our desires as of the date of this official statement and talk just as of the beginning date of this public statement. We embrace no commitment to freely upgrade or change any forward-looking proclamation, whether as a consequence of new data, future occasions or something else.
The Senhance will be accessible for specialist assessments at the congress. Specialists may plan framework assessments by joining at the TransEnterix corner. Dr. Salvatore Gueli Alletti from the Division of Gynecologic Oncology at the Catholic University of the Sacred Heart in Rome, Italy, will feature an extraordinary symposium committed to the clinical experience of the Senhance in Gynecologic Surgery. The symposium will be hung on the morning of Wednesday, November 16, 2016, and members must enroll through the AAGL to go to.
The Senhance conveys the CE Mark for use all in all surgery, gynecology, urology and thoracic surgery yet is not accessible available to be purchased in the US. TransEnterix is setting up a 510(k) accommodation for the Senhance.
About TransEnterix
TransEnterix is a restorative gadget organization that is spearheading the utilization of apply autonomy to enhance negligibly intrusive surgery by tending to the clinical and monetary difficulties connected with current laparoscopic and mechanical alternatives. The organization is centered around the commercialization of the Senhance Surgical Robotic System, a multi-port automated framework that conveys the benefits of mechanical surgery to patients while empowering specialists with imaginative innovation, for example, haptic input and eye detecting camera control. The organization is likewise building up the SurgiBot™ System, a solitary port, mechanically upgraded laparoscopic surgical stage. The Senhance Surgical Robotic System has been allowed a CE Mark however is not right now accessible available to be purchased in the United States. For more data, visit the TransEnterix site at www.transenterix.com.
Forward Looking Statements
This official statement incorporates articulations identifying with The Senhance™ Surgical Robotic System and our current administrative and commercialization gets ready for this item. These announcements and different articulations in regards to our feasible arrangements and objectives constitute "forward looking proclamations" inside the importance of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are proposed to meet all requirements for the protected harbor from obligation set up by the Private Securities Litigation Reform Act of 1995. Such proclamations are liable to dangers and vulnerabilities that are frequently hard to foresee, are outside our ability to control and which may make comes about vary tangibly from desires, including whether and when we will set up a 510(k) accommodation for the Senhance Surgical Robotic System. For a dialog of the dangers and vulnerabilities connected with TransEnterix's business, please audit our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K documented on March 3, 2016 and our different filings we make with the SEC. You are advised not to place undue dependence on these forward looking articulations, which depend on our desires as of the date of this official statement and talk just as of the beginning date of this public statement. We embrace no commitment to freely upgrade or change any forward-looking proclamation, whether as a consequence of new data, future occasions or something else.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.